A comprehensive intellectual property protection program has been put in place to support the roll-out of PromarkerD.
The PromarkerD diabetic kidney disease test:
- Patents secured in the USA1, Europe, Japan, Australia, Russia, Singapore, Indonesia and China (covering a potential market size of 214 million diabetics).
- Patents pending in Brazil and India (covering a potential market size of 72 million diabetics).
Exclusive licensing to a family of allied patents for the diagnosis of kidney damage has been secured. This provides immediate protection for the PromarkerD test in Europe, and extends PromarkerD’s patent protection in the US to include other forms of kidney disease.
This exclusive license has the potential to extend PromarkerD‘s clinical utility to include the prediction of any form of kidney disease. It also has the potential to enable PromarkerD to be used as an endpoint marker in clinical trials for any new drug.
“Promarker” is a registered trademark in Australia. Registration is pending in other major jurisdictions.
1. US 9,146,243 B2, “Method of assessing diabetic nephropathy using CD5 antigen-like”